These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 17020475)

  • 21. LRRK2 mutations in a clinic-based cohort of Parkinson's disease.
    Scholz S; Mandel RJ; Fernandez HH; Foote KD; Rodriguez RL; Barton E; Munson S; Singleton A; Okun MS
    Eur J Neurol; 2006 Dec; 13(12):1298-301. PubMed ID: 17116211
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High frequency and reduced penetrance of LRRK2 G2019S mutation among Parkinson's disease patients in Cantabria (Spain).
    Sierra M; González-Aramburu I; Sánchez-Juan P; Sánchez-Quintana C; Polo JM; Berciano J; Combarros O; Infante J
    Mov Disord; 2011 Nov; 26(13):2343-6. PubMed ID: 21954089
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comprehensive screening of a North American Parkinson's disease cohort for LRRK2 mutation.
    Johnson J; Paisán-Ruíz C; Lopez G; Crews C; Britton A; Malkani R; Evans EW; McInerney-Leo A; Jain S; Nussbaum RL; Foote KD; Mandel RJ; Crawley A; Reimsnider S; Fernandez HH; Okun MS; Gwinn-Hardy K; Singleton AB
    Neurodegener Dis; 2007; 4(5):386-91. PubMed ID: 17622782
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MAPK-pathway activity, Lrrk2 G2019S, and Parkinson's disease.
    White LR; Toft M; Kvam SN; Farrer MJ; Aasly JO
    J Neurosci Res; 2007 May; 85(6):1288-94. PubMed ID: 17385669
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Neuropsychological performance in LRRK2 G2019S carriers with Parkinson's disease.
    Alcalay RN; Mejia-Santana H; Mirelman A; Saunders-Pullman R; Raymond D; Palmese C; Caccappolo E; Ozelius L; Orr-Urtreger A; Clark L; Giladi N; Bressman S; Marder K;
    Parkinsonism Relat Disord; 2015 Feb; 21(2):106-10. PubMed ID: 25434972
    [TBL] [Abstract][Full Text] [Related]  

  • 26. G2019S mutation of the leucine-rich repeat kinase 2 gene in a cohort of Egyptian patients with Parkinson's disease.
    Hashad DI; Abou-Zeid AA; Achmawy GA; Allah HM; Saad MA
    Genet Test Mol Biomarkers; 2011 Dec; 15(12):861-6. PubMed ID: 21699405
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mutations in LRRK2 other than G2019S are rare in a north American-based sample of familial Parkinson's disease.
    Pankratz N; Pauciulo MW; Elsaesser VE; Marek DK; Halter CA; Rudolph A; Shults CW; Foroud T; Nichols WC;
    Mov Disord; 2006 Dec; 21(12):2257-60. PubMed ID: 17078063
    [TBL] [Abstract][Full Text] [Related]  

  • 28. REM sleep behavior disorder, as assessed by questionnaire, in G2019S LRRK2 mutation PD and carriers.
    Saunders-Pullman R; Alcalay RN; Mirelman A; Wang C; Luciano MS; Ortega RA; Glickman A; Raymond D; Mejia-Santana H; Doan N; Johannes B; Yasinovsky K; Ozelius L; Clark L; Orr-Utreger A; Marder K; Giladi N; Bressman SB;
    Mov Disord; 2015 Nov; 30(13):1834-9. PubMed ID: 26366513
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Age-specific penetrance of LRRK2 G2019S in the Michael J. Fox Ashkenazi Jewish LRRK2 Consortium.
    Marder K; Wang Y; Alcalay RN; Mejia-Santana H; Tang MX; Lee A; Raymond D; Mirelman A; Saunders-Pullman R; Clark L; Ozelius L; Orr-Urtreger A; Giladi N; Bressman S;
    Neurology; 2015 Jul; 85(1):89-95. PubMed ID: 26062626
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Low-variance RNAs identify Parkinson's disease molecular signature in blood.
    Chikina MD; Gerald CP; Li X; Ge Y; Pincas H; Nair VD; Wong AK; Krishnan A; Troyanskaya OG; Raymond D; Saunders-Pullman R; Bressman SB; Yue Z; Sealfon SC
    Mov Disord; 2015 May; 30(6):813-21. PubMed ID: 25786808
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High prevalence of LRRK2 mutations in familial and sporadic Parkinson's disease in Portugal.
    Ferreira JJ; Guedes LC; Rosa MM; Coelho M; van Doeselaar M; Schweiger D; Di Fonzo A; Oostra BA; Sampaio C; Bonifati V
    Mov Disord; 2007 Jun; 22(8):1194-201. PubMed ID: 17469194
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prevalence and clinical features of common LRRK2 mutations in Australians with Parkinson's disease.
    Huang Y; Halliday GM; Vandebona H; Mellick GD; Mastaglia F; Stevens J; Kwok J; Garlepp M; Silburn PA; Horne MK; Kotschet K; Venn A; Rowe DB; Rubio JP; Sue CM
    Mov Disord; 2007 May; 22(7):982-9. PubMed ID: 17427941
    [TBL] [Abstract][Full Text] [Related]  

  • 33. LRRK2 G2019S mutation does not contribute to Parkinson's disease in South India.
    Vijayan B; Gopala S; Kishore A
    Neurol India; 2011; 59(2):157-60. PubMed ID: 21483109
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Genetic screening for the LRRK2, G2019S and R1441 codon mutations in Parkinson's disease patients from Extremadura, Spain].
    Morán JM; Castellanos-Pinedo F; Casado-Naranjo I; Durán-Herrera C; Ramírez-Moreno JM; Gómez M; Zurdo-Hernández JM; Fuentes E; Ortiz-Ortiz MA; Moreno AD; González-Polo RA; Niso-Santano M; Bravo-Sanpedro JM; Pérez-Tur J; Ruiz-Mesa LM; Fuentes JM
    Rev Neurol; 2010 May; 50(10):591-4. PubMed ID: 20473834
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical and imaging markers in premotor LRRK2 G2019S mutation carriers.
    Vilas D; Ispierto L; Álvarez R; Pont-Sunyer C; Martí MJ; Valldeoriola F; Compta Y; de Fabregues O; Hernández-Vara J; Puente V; Calopa M; Jaumà S; Campdelacreu J; Aguilar M; Quílez P; Casquero P; Lomeña F; Ríos J; Tolosa E
    Parkinsonism Relat Disord; 2015 Oct; 21(10):1170-6. PubMed ID: 26306001
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Genetic analysis of LRRK2 mutations in patients with Parkinson disease.
    Deng H; Le W; Guo Y; Hunter CB; Xie W; Huang M; Jankovic J
    J Neurol Sci; 2006 Dec; 251(1-2):102-6. PubMed ID: 17097110
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Parkinson's disease-related LRRK2 G2019S mutation results from independent mutational events in humans.
    Lesage S; Patin E; Condroyer C; Leutenegger AL; Lohmann E; Giladi N; Bar-Shira A; Belarbi S; Hecham N; Pollak P; Ouvrard-Hernandez AM; Bardien S; Carr J; Benhassine T; Tomiyama H; Pirkevi C; Hamadouche T; Cazeneuve C; Basak AN; Hattori N; Dürr A; Tazir M; Orr-Urtreger A; Quintana-Murci L; Brice A;
    Hum Mol Genet; 2010 May; 19(10):1998-2004. PubMed ID: 20197411
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Frequency of the LRRK2 G2019S mutation in siblings with Parkinson's disease.
    Lesage S; Leclere L; Lohmann E; Borg M; Ruberg M; Dürr A; Brice A;
    Neurodegener Dis; 2007; 4(2-3):195-8. PubMed ID: 17596714
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hyposmia in G2019S LRRK2-related parkinsonism: clinical and pathologic data.
    Silveira-Moriyama L; Guedes LC; Kingsbury A; Ayling H; Shaw K; Barbosa ER; Bonifati V; Quinn NP; Abou-Sleiman P; Wood NW; Petrie A; Sampaio C; Ferreira JJ; Holton J; Revesz T; Lees AJ
    Neurology; 2008 Sep; 71(13):1021-6. PubMed ID: 18809839
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A study of LRRK2 mutations and Parkinson's disease in Brazil.
    Pimentel MM; Moura KC; Abdalla CB; Pereira JS; de Rosso AL; Nicaretta DH; Campos M; de Almeida RM; dos Santos JM; Bastos IC; Mendes MF; Maultasch H; Costa FH; Werneck AL; Santos-Rebouças CB
    Neurosci Lett; 2008 Mar; 433(1):17-21. PubMed ID: 18201824
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.